New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 22, 2014
06:09 EDTCELGCelgene makes changes in its leadership team
Celgene announced organizational changes that will go into effect on August 1. Mark Alles is promoted to President and COO. Jacqualyn Fouse, PhD, is promoted to President Hematology & Oncology after four years as Celgene’s CFO. Scott Smith is promoted to President Inflammation & Immunology, which he has led since 2009 from its early development stages. Peter Kellogg joins Celgene as Executive VP, CFO. Mark Alles is transitioning from his current role as Head of Hematology & Oncology franchise having previously held multiple positions over his ten years at Celgene.
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2015
07:12 EDTCELGWilliam Blair names 21 stocks best positioned for volatile markets
Subscribe for More Information
August 27, 2015
16:03 EDTCELGCelgene completes acquisition of Receptos
Subscribe for More Information
August 25, 2015
07:31 EDTCELGCelgene announces expiration of tender offer for Receptos shares
Subscribe for More Information
August 24, 2015
18:55 EDTCELGOn The Fly: After Hours Movers
Subscribe for More Information
18:52 EDTCELGJazz, Celgene, Shire up after USPTO rejects Acorda patent challenge
Subscribe for More Information
13:36 EDTCELGBiotech correction presents some opportunities, says RBC Capital
RBC Capital analyst Michael Yee said he won't try to pick the short-term bottom in biotech, but contends that any macro weakness in China shouldn't have any major impact to financials or fundamentals for the sector given their minimal exposure there. If the market continues to be volatile, Yee recommends a focus on names with defensive characteristics, such as higher margins and free cash flow yield, naming Amgen (AMGN), Celgene (CELG) and Gilead (GILD) as some examples. The analyst adds that he likes Vertex (VRTX) on the pullback for "more aggressive" growth investors. Yee has Outperform ratings on all of the stocks mentioned above.
August 23, 2015
12:35 EDTCELGBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use